(Q36543128)

14 August 2017

1 reference

title

Pharmacogenetics of chronic cardiovascular drugs: applications and implications (English)

1 reference

14 August 2017

Issam Zineh

1

1 reference

14 August 2017

Julie A Johnson

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

11

1 reference

14 August 2017

page(s)

1417-1427

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Variability in response to antihypertensive drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The influence of ethnicity on warfarin dosage requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Variants of the CYP11B2 gene predict response to therapy with candesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The forgotten majority: unfinished business in cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Genetic polymorphisms and statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Genetic regulation of warfarin metabolism and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

CYP2C9 polymorphism and warfarin dose requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

The genetic basis of resistance to anticoagulants in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Integrating pharmacogenetics into society: in search of a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

ACE and α-Adducin Polymorphism as Markers of Individual Response to Diuretic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

Chromosome 2p Shows Significant Linkage to Antihypertensive Response in the British Genetics of Hypertension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.11.1417

10.1517/14656566.7.11.1417

21 January 2018

Identifiers

DOI

1 reference

release_agm4czwgfbchrif6e54v7fn7se

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/agm4czwgfbchrif6e54v7fn7se

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference